Dietmar Hopp (Photo by: Uwe Anspach/picture-alliance/dpa/AP Images)
February 28, 2022 07:06 AM ESTUpdated 08:50 AM
Deals

In all-en­com­pass­ing rights deal with Huadong, Di­et­mar Hop­p's Hei­del­berg looks to bring its AD­Cs to most of Asia

Max Gelman

Senior Editor

Just a few days af­ter Ger­man bil­lion­aire in­vestor Di­et­mar Hopp sunk some of his cash in­to Hei­del­berg Phar­ma, the biotech is cel­e­brat­ing a new li­cens­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Ex­clu­sive: Flag­ship names two CEO-part­ners to lead Va­lo Health, Apri­ori Bio

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times